Pelthos Therapeutics Inc.
PTHS- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001919246
In the last 90 days, Pelthos Therapeutics Inc. insiders filed 0 open-market purchases and 3 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $38.5M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $55.9K in total
- 3
- 13F holdersQ2 2026, +7 vs. previous quarter
- 24
- 13F valueReported value at the end of Q2 2026
- $38.5M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding PTHS, Q2 2026
No superinvestor reported holding PTHS at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Pelthos Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 (view filing)5:03 PM ET | Jul 2 | 5 days | Friedberg Ezra MDirector | SSale | −558 | $26.09 | −$14.6K | −0.7%81.0K after | 2 lots10b5-1 |
| Jul 7, 2026 (view filing)5:03 PM ET | Jul 2 | 5 days | Pauls MatthewDirector | SSale | −786 | $26.16 | −$20.6K | −5.2%14.4K after | 2 lots10b5-1 |
| Jul 7, 2026 (view filing)5:03 PM ET | Jul 2 | 5 days | Greenleaf PeterDirector | SSale | −797 | $26.13 | −$20.8K | −3.2%23.9K after | 2 lots10b5-1 |
| Jun 17, 2026 (view filing) | Jun 15 | 2 days | Friedberg Ezra MDirector | SSale | −283 | $27.29 | −$7.72K | −0.3%81.6K after | 2 lots10b5-1 |
| Jun 15, 2026 (view filing) | Jun 11 | 4 days | Davis Todd CDirector | PPurchase | +35.9K | $27.81 | +$999.8K | +90.1%75.8K after | 2 lots |
| May 26, 2026 (view filing) | May 22 | 4 days | Francis Knuettel IICFO, Treas & Secty | SSale | −1.50K | $26.84 | −$40.3K | −11.7%11.3K after | |
| Apr 6, 2026 (view filing) | Apr 2 | 4 days | Malamut RichardDirector | SSale | −590 | $20.91 | −$12.3K | −2.1%27.4K after | 2 lots10b5-1 |
| Apr 6, 2026 (view filing) | Apr 2 | 4 days | Friedberg Ezra MDirector | SSale | −558 | $20.91 | −$11.7K | −0.7%82.0K after | 2 lots10b5-1 |
| Apr 6, 2026 (view filing) | Apr 2 | 4 days | Pauls MatthewDirector | SSale | −786 | $20.92 | −$16.4K | −4.9%15.2K after | 2 lots10b5-1 |
| Apr 6, 2026 (view filing) | Apr 2 | 4 days | Greenleaf PeterDirector | SSale | −797 | $20.92 | −$16.7K | −3.1%24.7K after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Pelthos Therapeutics Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AIGH Capital Management LLC | 329,098 | $9.30M | 0.84% | +329,098 | New |
| Murchinson Ltd. | 304,302 | $8.60M | 4.15% | +7,988+2.7% | Added |
| Ikarian Capital, LLC | 256,598 | $7.25M | 1.19% | 00.0% | Unchanged |
| Boothbay Fund Management, LLC | 101,976 | $2.88M | 0.05% | +20,118+24.6% | Added |
| Vanguard Capital Management LLC | 97,134 | $2.75M | 0.00% | +4,041+4.3% | Added |
| Cantor Fitzgerald, L. P. | 76,246 | $2.15M | 0.02% | +34,823+84.1% | Added |
| J. Goldman & Co LP | 38,075 | $1.08M | 0.04% | −12,340−24.5% | Reduced |
| Diadema Partners LP | 24,773 | $700.1K | 0.25% | 00.0% | Unchanged |
| Wexford Capital LP | 22,364 | $632.0K | 0.09% | +22,364 | New |
| Knott David M Jr | 22,073 | $623.8K | 0.33% | +1,000+4.7% | Added |